During the past decade, Centre Neurologique William Lennox conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 3 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Neurologique William Lennox" #1 sponsor was "Cliniques universitaires Saint-Luc- Université Catholique de Louvain" with 2 trials, followed by "GlaxoSmithKline" with 2 trials sponsored, "Takeda" with 2 trials sponsored, "Bial - Portela C S.A." with 1 trials sponsored and "Eisai Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Neurologique William Lennox" #1 collaborator was "Bausch Health Americas, Inc." with 1 trials as a collaborator, "Centre Hospitalier Universitaire Dinant Godinne - UCL Namur" with 1 trials as a collaborator and "Sunovion" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Centre Neurologique William Lennox" are "Lennox Gastaut Syndrome (LGS)" (2 trials), "Acute Stroke" (1 trials), "Brain Injuries" (1 trials), "Central Nervous System Diseases" (1 trials) and "Cerebral Palsy" (1 trials). Many other conditions were trialed in "Centre Neurologique William Lennox" in a lesser frequency.

Most popular intervention types in "Centre Neurologique William Lennox" are "Drug" (7 trials), "Device" (2 trials), "Behavioral" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Soticlestat" (2 trials), "1200 mg QD Eslicarbazepine acetate" (1 trials), "800 mg QD Eslicarbazepine acetate" (1 trials) and "Active taVNS" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centre Neurologique William Lennox" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Centre Neurologique William Lennox". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Centre Neurologique William Lennox, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Neurologique William Lennox, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".